Skip to content
ChickenStockChickenStock
ResearchFilings

AI English summary of an SEC filing — figures as filed

Zimmer Biomet logoZimmer Biomet ZBH

The company said the Board on June 20, 2024 increased its size from 10 members to 11 members and appointed Devdatt Kurdikar as a director, with his term expiring at the 2025 annual shareholders meeting.

8-KDeparture or Appointment of Directors or Certain OfficersFiled Period of report Summary published (UTC)

Key points

AI summary

  1. The company said the Board on June 20, 2024 increased its size from 10 members to 11 members and appointed Devdatt Kurdikar as a director, with his term expiring at the 2025 annual shareholders meeting.

  2. The company said Kurdikar was assigned to the Corporate Governance Committee and the Compensation and Management Development Committee, and that there are no arrangements for his appointment and no material interest requiring disclosure under Item 404(a).

  3. Zimmer Biomet said Kurdikar will participate in the non-employee director compensation arrangements described in the proxy statement filed on March 27, 2024, and is expected to sign the company's standard non-employee director indemnification agreement.

  4. In its press release, the company said Kurdikar is President, Chief Executive Officer and a director of embecta Corp., and that he served as Worldwide President of Diabetes Care at BD from 2021 until the spinoff.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Board expanded from 10 to 11 members; Devdatt Kurdikar appointed

The company said the Board on June 20, 2024 increased its size from 10 members to 11 members and appointed Devdatt Kurdikar as a director, with his term expiring at the 2025 annual shareholders meeting.

Source · Based on the filing body and exhibits

Kurdikar committee assignments; no related interests

The company said Kurdikar was assigned to the Corporate Governance Committee and the Compensation and Management Development Committee, and that there are no arrangements for his appointment and no material interest requiring disclosure under Item 404(a).

Source · Based on the filing body and exhibits

Non-employee director pay; indemnification agreement expected

Zimmer Biomet said Kurdikar will participate in the non-employee director compensation arrangements described in the proxy statement filed on March 27, 2024, and is expected to sign the company's standard non-employee director indemnification agreement.

Source · Based on the filing body and exhibits

Kurdikar's current role and prior BD experience

In its press release, the company said Kurdikar is President, Chief Executive Officer and a director of embecta Corp., and that he served as Worldwide President of Diabetes Care at BD from 2021 until the spinoff.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗
Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.